GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Rozanolixizumab - RYSTIGGO subcutaneous infusion

Read renal action and limits
Local official-label summarySource retrieved 2026-11-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

RYSTIGGO / rozanolixizumab

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

RYSTIGGO: source applicability and renal evidence limits

An explicit no-adjustment instruction and a limited supporting study range can coexist. Preserve both; do not label an unstudied dialysis regimen as clinically validated.

Before applying: Subcutaneous infusion only; use the labeled weight-based regimen.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

RYSTIGGO: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.

Renal action / finding
Label: no renal adjustment required.
Evidence or dialysis limit
Evidence is population PK, not a dedicated severe-renal or dialysis study.
Monitoring / application
Subcutaneous infusion only; use the labeled weight-based regimen.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.
Renal measure
Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Evidence is population PK, not a dedicated severe-renal or dialysis study.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Section 12.3, Patients with Renal Impairment

The label states no dose adjustment is required with renal impairment. No dedicated renal PK study was performed; population data included mild/moderate impairment, with eGFR 38-161 mL/min/1.73 m2. This explicit instruction is retained without claiming that severe impairment or dialysis was directly validated.

Source revision: Revision date not captured in selected review; retrieval date is not revision date. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

RYSTIGGO: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

RYSTIGGO: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

RYSTIGGO: selected primary-label renal guidance and limits

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Evidence is population PK, not a dedicated severe-renal or dialysis study.

Dialysis evidence: No dialysis regimen established in selected content

Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.

Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

RYSTIGGO: selected RX renal passage

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Evidence is population PK, not a dedicated severe-renal or dialysis study.

Dialysis evidence: No dialysis regimen established in selected content

Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.

Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

RYSTIGGO: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

RYSTIGGO: source applicability and renal evidence limits

An explicit no-adjustment instruction and a limited supporting study range can coexist. Preserve both; do not label an unstudied dialysis regimen as clinically validated.

How to use this: Subcutaneous infusion only; use the labeled weight-based regimen.

RYSTIGGO: selected primary-label renal guidance and limitsRYSTIGGO: selected RX renal passage

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeRYSTIGGO: selected primary-label renal guidance and limitsRYSTIGGO: selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

An RX mirror and its underlying label are not independent clinical confirmations.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1

Product identity and scope

Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.

RDM72-rozanolixizumab-rystiggo-scope · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

RYSTIGGO: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.

Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source date: Revision date not captured in selected review; retrieval date is not revision date.
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Evidence is population PK, not a dedicated severe-renal or dialysis study.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 12.3, Patients with Renal Impairment

The label states no dose adjustment is required with renal impairment. No dedicated renal PK study was performed; population data included mild/moderate impairment, with eGFR 38-161 mL/min/1.73 m2. This explicit instruction is retained without claiming that severe impairment or dialysis was directly validated.

RDM72-rozanolixizumab-rystiggo-label-1 · Source locator: Section 12.3, Patients with Renal Impairment

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1
Retrieved
2026-11-07
Renal-function method
Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source date/version
Revision date not captured in selected review; retrieval date is not revision date.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
5a84f2af8694d7bd679768d82b237114ba627c4c54ea4079921ea9d48c920766
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

RYSTIGGO: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult RYSTIGGO subcutaneous infusion for labeled generalized myasthenia gravis; not intravenous administration.

Renal method: Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Evidence is population PK, not a dedicated severe-renal or dialysis study.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 12.3, Patients with Renal Impairment

The mirror includes the no-adjustment instruction and a population-PK range of eGFR 38-161 mL/min/1.73 m2. A dedicated renal study was not conducted.

RDM72-rozanolixizumab-rystiggo-rx-1 · Source locator: Section 12.3, Patients with Renal Impairment

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/rystiggo-drug/
Retrieved
2026-11-07
Renal-function method
Population PK: indexed eGFR 38-161 mL/min/1.73 m2
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
bacc7d40588d5af26162560ea00a11e570fe003aa7fec1e4c6c561d512c3bbbc

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c0eb8c2-c042-4954-b451-3baa77f5e6d1
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
c5ec8ede691ae8294f8257e455c38040f2549ada4d082f89e5f30353179dcf5f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top